Return on Invested Capital (ROIC): 8.84%
Is the return on invested capital (ROIC) high or low?
The return on invested capital (ROIC) of 8.84% is in line with its 5-year average of 9.38%, around the middle of its 5-year range (6.79%–11.58%).
As of Monday, June 29, 2026. 3.21% above its 12-month average of 8.56%.
GEHC Return on Invested Capital (ROIC) Chart
Annual fiscal-year return on invested capital; no daily interpolation.
GEHC Average Return on Invested Capital (ROIC) Chart
GEHC Current vs Average Return on Invested Capital (ROIC) Chart
GEHC Return on Invested Capital (ROIC) Metrics
RETURN ON INVESTED CAPITAL (ROIC)
8.84%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
8.56%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
8.37%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
9.38%
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
N/A
CURRENT VS TTM AVG
+3.21%
CURRENT VS 3Y AVG
+5.62%
CURRENT VS 5Y AVG
-5.81%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
GEHC Competitors' Return on Invested Capital (ROIC)
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| GE HealthCare Technologies Inc. (GEHC) | $29.00B | 8.84% | 8.56% | 8.37% | 9.38% |
| Veeva Systems Inc. (VEEV)vs › | $28.51B | 9.48% | 9.25% | 9.54% | 11.31% |
| Moderna, Inc. (MRNA)vs › | $28.27B | -29.70% | -31.12% | -12.69% | 0.19% |
| ResMed Inc. (RMD)vs › | $28.21B | 19.56% | 18.66% | 17.73% | 16.77% |
| Zoetis Inc. (ZTS)vs › | $30.01B | 21.54% | 21.87% | 20.30% | 19.27% |
| DexCom, Inc. (DXCM)vs › | $26.37B | 16.61% | 13.40% | 11.07% | 9.62% |
| Centene Corp. (CNC)vs › | $31.68B | -13.41% | -4.17% | -0.53% | 0.76% |
| IQVIA Holdings Inc. (IQV)vs › | $31.89B | 8.23% | 8.41% | 8.23% | 6.99% |
| Biogen Inc. (BIIB)vs › | $31.98B | 6.62% | 7.71% | 8.64% | 10.90% |
| Mettler-Toledo International Inc. (MTD)vs › | $25.75B | 35.46% | 38.26% | 37.51% | 36.01% |
Capital Efficiency
ROIC
8.8%
ROE
14.1%
Return on Invested Capital (ROIC) Formula & Definition
ROIC = NOPAT / Invested Capital
Return on invested capital measures the after-tax return a company earns on all capital (debt and equity) invested in the business.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Return on Invested Capital (ROIC) FAQ
- What is the return on invested capital (ROIC) for GE HealthCare Technologies Inc. (GEHC)?
- The return on invested capital (ROIC) for GEHC stock is 8.84%.
- Is GE HealthCare Technologies Inc.'s return on invested capital (ROIC) high or low?
- The return on invested capital (ROIC) of 8.84% is in line with its 5-year average of 9.38%, around the middle of its 5-year range (6.79%–11.58%).
- What is the TTM average return on invested capital (ROIC) for GE HealthCare Technologies Inc. (GEHC)?
- The TTM average return on invested capital (ROIC) for GEHC stock is 8.56%.
- What is the 3Y average return on invested capital (ROIC) for GE HealthCare Technologies Inc. (GEHC)?
- The 3Y average return on invested capital (ROIC) for GEHC stock is 8.37%.
- What is the 5Y average return on invested capital (ROIC) for GE HealthCare Technologies Inc. (GEHC)?
- The 5Y average return on invested capital (ROIC) for GEHC stock is 9.38%.
GEHC Return on Invested Capital (ROIC) History
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2025-12-31 | 8.84% |
| 2024-12-31 | 8.29% |
| 2023-12-31 | 6.79% |
| 2022-12-31 | 9.56% |
| 2021-12-31 | 11.25% |
| 2020-12-31 | 11.58% |
| 2019-12-31 | 0.00% |
Related Metrics
About GE HealthCare Technologies Inc.
GE HealthCare Technologies Inc. is a global medical technology company that creates, manufactures, and markets a diverse range of medical devices, services, and integrated digital solutions. These offerings are designed to assist in the diagnosis, treatment, and ongoing monitoring of patients. The company boasts an extensive international presence, serving markets across the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, and Hong Kong, among other regions. Its operations are structured across four primary business divisions: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging division specializes in advanced diagnostic imaging technologies, including systems for molecular imaging, Computed Tomography (CT) scans, Magnetic Resonance (MR) imaging, image-guided therapy, and X-ray, alongside specialized women's health products. The Ultrasound segment delivers a comprehensive suite of ultrasound solutions utilized for the screening, diagnosis, treatment, and monitoring of various diseases. These applications span radiology, primary care, women's health, cardiovascular diagnostics, point-of-care, and portable handheld devices, in addition to products supporting surgical visualization and guidance. The Patient Care Solutions segment is dedicated to providing essential medical devices, consumable products, services, and digital platforms. Its portfolio encompasses patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal-infant care products. The Pharmaceutical Diagnostics segment supplies specialized diagnostic agents to the radiology and nuclear medicine industries. These include contrast media pharmaceuticals, administered to patients prior to scans like CT, angiography, X-ray, and MR, to enhance the visibility of internal tissues and structures. It also offers molecular imaging agents, or radiopharmaceuticals – molecular tracers labeled with radioisotopes – injected into patients for advanced diagnostic imaging applications such as Single-Photon Emission Computed Tomography (SPECT), Positron Emission Tomography (PET), and specific ultrasound procedures. Established in 2022, GE HealthCare Technologies Inc. maintains its corporate headquarters in Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- CEO
- Peter J. Arduini